A single‐tablet formulation (fixed‐dose combination [FDC]) of macitentan/tadalafil provides PAH patients the efficacy and safety of a combined use of macitentan and a PDE‐5 inhibitor in one formulation facilitating a high level of compliance and a low risk of medication errors. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.